HOCOR Cardiovascular Technologies
Our life-saving temporary heart valve catheter is 10 pigs away from FDA approval for human use.
HOCOR’s temporary heart valve catheter that can save lives in an emergent situation. Our invention has been awarded 8 patents (7US, 1EU), and the technology has been validated in 8 medical journal publications. The FDA said in a letter that we have reached the last round of animal study of 10 pigs before human use. The cost of this final step is estimated to be $750,000.